文献速递白血病

CPX-351治疗诱导死亡高风险急性髓系白血病患者的II期试验

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
PubMed 文献 · Leukemia · 2020-06-16

这项开放标签II期试验将诱导死亡高风险的急性髓系白血病患者随机分配至CPX-351 50或75单位/m2组(第1、3、5天给药),安全性确立后增设100单位/m2组,共入组56例。复合完全缓解率50单位/m2组为19%,75单位/m2组为38%,100单位/m2组为44%(P=0.35);中位总生存期分别为4.3、8.6和6.2个月(P=0.04)。作者认为75单位/m2剂量安全性好且有效,部分患者可耐受标准剂量100单位/m2。

要点

  • 50单位/m2组复合完全缓解率19%,75单位/m2组38%,100单位/m2组44%(P=0.35)。
  • 中位总生存期50单位/m2组4.3个月,75单位/m2组8.6个月,100单位/m2组6.2个月(P=0.04)。
  • 非血液学3/4级治疗中出现的不良事件包括发热性中性粒细胞减少(34%)、肺炎(23%)和脓毒症(16%)。

核心结论

  • CPX-351 75单位/m2对诱导死亡高风险的急性髓系白血病患者具有较好的安全性和疗效,部分患者可耐受标准剂量100单位/m2。

研究设计与样本

  • 开放标签II期试验,纳入诱导死亡高风险的急性髓系白血病患者,随机接受CPX-351 50或75单位/m2(第1、3、5天给药),安全性确立后增设100单位/m2组,共入组56例(50、75、100单位/m2组分别为16、24、16例)。

主要发现

  • 复合完全缓解率50单位/m2组为19%,75单位/m2组为38%,100单位/m2组为44%(P=0.35)。
  • 中位总生存期50单位/m2组为4.3个月,75单位/m2组为8.6个月,100单位/m2组为6.2个月(P=0.04)。
  • 非血液学3/4级治疗中出现的不良事件包括发热性中性粒细胞减少(34%)、肺炎(23%)和脓毒症(16%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CPX-351 is a liposomal formulation of cytarabine/daunorubicin with a 5:1 fixed molar ratio. We investigated the safety and efficacy of escalating doses of CPX-351 in patients with acute myeloid leukemia (AML) at high risk of induction mortality with standard chemotherapy determined through assessment of leukemia and patient-related risk factors for intensive chemotherapy in an open-label, phase II trial. Patients were randomized to receive 50 or 75 units/m2 on days 1, 3, and 5. Once safety was established, a 100 units/m2 arm was opened. Fifty-six patients were enrolled, 16, 24, and 16 in the 50, 75, and 100 units/m2 arms, respectively. The composite complete remission rate (complete remission + complete remission with incomplete blood count recovery) was lowest with 50 units/m2 (19%) compared with 75 units/m2 (38%) and 100 units/m2 (44%) (P = 0.35). The 50 units/m2 arm had a median OS of 4.3 months, compared with 8.6 and 6.2 months for the 75 and 100 units/m2 respectively (P = 0.04). Nonhematologic grade 3/4 treatment-emergent adverse events included febrile neutropenia (34%), pneumonia (23%), and sepsis (16%). CPX-351 at 75 units/m2 has favorable safety and efficacy for AML patients at high risk of induction mortality with some tolerating the standard dose of 100 units/m2.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Issa GC, Kantarjian HM, Xiao L, et al. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020. PMID: 32546726. doi:10.1038/s41375-020-0916-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。